Crescita Therapeutics Inc.
Crescita Therapeutics Inc. (CTX.TO) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
ctx.to · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Crescita Therapeutics Inc. (CTX.TO) measures how much investors pay for each dollar of the company's trailing earnings. CTX.TO's current PE ratio of N/A is calculated by dividing its stock price of $0.79 by its TTM earnings per share of -$0.02.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2014 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 4 fiscal years · Front-end computedMinQ1 · 25%13.2x
MedianQ3 · 75%390.9x
Max
At N/A, CTX.TO's current P/E is lower than in 0% of its annual fiscal year readings over the past 4 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Crescita Therapeutics Inc.You CTX.TO | $15M | N/A | — | -$0.02 |
 Avant Brands Inc. AVNT.TO | $7M | N/A | — | -$0.88 |
 Ayurcann Holdings Corp. AYUR.CN | $2M | N/A | — | -$0.02 |
 Blueberries Medical Corp. BBM.CN | $5M | N/A | — | -$0.00 |
 BetterLife Pharma Inc. BETR.CN | $11M | N/A | — | -$0.01 |
 CLS Holdings USA, Inc. CLSH.CN | $8M | N/A | — | -$0.05 |
 Delivra Health Brands Inc. DHB.V | $4M | N/A | — | -$0.04 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-0.00 | — | |
2024-12-31 FY2024 | — | $-0.14 | — | |
2023-12-31 FY2023 | — | $-0.10 | — | |
2022-12-31 FY2022 | 15.84x | $0.04 | — | |
2021-12-31 FY2021 | — | $-0.05 | — | |
2020-12-31 FY2020 | 390.89x | $0.00 | +3623.1% | |
2019-12-31 FY2019 | 10.50x | $0.09 | +186.9% | |
2018-12-31 FY2018 | 3.66x | $0.12 | — | |
2017-12-31 FY2017 | — | $-0.82 | — | |
2016-12-31 FY2016 | — | $-1.22 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Crescita Therapeutics Inc. (CTX.TO) measures how much investors pay for each dollar of the company's trailing earnings. CTX.TO's current PE ratio of N/A is calculated by dividing its stock price of $0.79 by its TTM earnings per share of -$0.02.
Frequently asked questions
CTX.TO pe ratio · 6 questionsCTX.TO's current PE ratio is N/A as of 2026-06-08, based on a stock price of $0.79 and TTM EPS of -$0.02. Data sourced from Financial Modeling Prep via CTX.TO's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Crescita Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08